Form 4: Kura Oncology COO Sells Shares for Tax Purposes
Insider Transaction Report
Kura Oncology's Chief Operating Officer, Kathleen Ford, sold 1,813 shares of common stock to cover tax obligations related to RSU vesting.
Summary
- Kathleen Ford, Chief Operating Officer of Kura Oncology, Inc., executed a sale of 1,813 shares of the company's common stock.
- The transaction took place on January 27, 2026, with shares sold at a price of $8.4607 per share.
- This sale was identified as a "sell-to-cover" transaction, specifically to satisfy tax liabilities associated with the vesting of a Restricted Stock Unit (RSU) that was granted to the Reporting Person on January 26, 2022.
- Following this reported transaction, Kathleen Ford directly beneficially owns 153,560 shares of Kura Oncology common stock.
Sentiment
Score: 5
Explanation: The transaction is a routine 'sell-to-cover' for tax purposes related to RSU vesting, which is a neutral event and does not indicate positive or negative sentiment towards the company's prospects.
Future Outlook
No forward-looking statements or guidance are provided in this Form 4 filing.
Industry Context
This routine insider transaction, a sell-to-cover for tax purposes, is a common occurrence for executives receiving equity compensation across various industries, including biotechnology. It does not inherently reflect broader industry trends or competitive positioning.
Comparison to Industry Standards
- This is a standard 'sell-to-cover' transaction, a common practice across all industries, including biotechnology, when equity awards like RSUs vest. It is not comparable to specific company projects or results.
Related Party Transactions
- The transaction involves an executive (Kathleen Ford) and the company's stock, which is a related party transaction in the context of insider reporting, but it is a standard compensation-related event.
Stakeholder Impact
- Minimal impact on shareholders as this is a routine, tax-related sale of a small portion of an executive's holdings.
- No direct impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 01/26/2022 | Date of RSU grant to the Reporting Person. |
| 01/27/2026 | Date of common stock transaction (sale) by the Reporting Person. |
Keywords
Kura Oncology, KURA, Kathleen Ford, COO, Form 4, Insider Trading, Stock Sale, RSU Vesting, Sell-to-cover, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.